Related Experiment Video
Updated: May 21, 2026
14:14
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Transapical aortic valve implantation: mid-term outcome from the SOURCE registry
Olaf Wendler1, Thomas Walther, Holger Schroefel
1Department of Cardiothoracic Surgery, King's Health Partners, London, UK. olaf.wendler@nhs.net
Summary
Transapical aortic valve implantation shows excellent mid-term results in elderly patients with severe comorbidities. Non-cardiac causes, often related to comorbidities, are the primary drivers of death during follow-up.
Area of Science:
- Cardiology
- Interventional Cardiology
- Bioprosthetics
Background:
- Transapical (TA) aortic valve implantation using the Edwards SAPIEN bioprosthesis was introduced in Europe in 2008.
- Limited mid-term outcome data exist for this procedure.
Purpose of the Study:
- To report on the mid-term results (30 days to 2 years) of TA aortic valve implantation.
- To analyze survival rates and causes of death in a large European cohort.
Main Methods:
- Utilized data from the SOURCE-Registry, Europe's largest consecutive cohort for the Edwards SAPIEN bioprosthesis.
- Included 1387 patients from 38 European centers undergoing TA aortic valve implantation between November 2007 and December 2009.
- Mean follow-up was 14.9 months, with 1-year and 2-year follow-up data available for 1004 and 464 patients, respectively.
Main Results:
- Mean patient age was 80.6 years with a logistic-EuroSCORE of 27.6%. Common comorbidities included coronary artery disease (55.8%) and peripheral vascular disease (26.4%).
- Survival rates at 30 days, 1 year, and 2 years were 88.7%, 73.8%, and 65.1%, respectively.
- Of 276 deaths between 30 days and 2 years, 51.4% were non-cardiac, primarily due to pulmonary disease, cancer, and renal failure.
Conclusions:
- Transapical aortic valve implantation demonstrates excellent mid-term outcomes in elderly patients with significant comorbidities.
- Non-cardiac conditions and comorbidities are the main contributors to mortality during the mid-term follow-up period.
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:15Aortic Regurgitation I: Introduction
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...